Download PDF
Semin Thromb Hemost 2001; 27(6): 657-666
DOI: 10.1055/s-2001-18870
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Fibrin Degradation Products, Fibrin Monomer and Soluble Fibrin in Disseminated Intravascular Coagulation

John T. Horan1 , Charles W. Francis2
  • 1Hematology Unit, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • 2Vascular Medicine Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
Further Information

Publication History

Publication Date:
06 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Disseminated intravascular coagulation (DIC) is characterized by activation of hemostasis and fibrinolysis resulting in the formation of thrombin and plasmin, and the characteristic effects of these enzymes on plasma fibrinogen can be useful in diagnosis. Thrombin cleaves fibrinopeptides from fibrinogen, forming fibrin monomer that rapidly polymerizes to form a clot. Small amounts can circulate in plasma as ``soluble fibrin,'' which may have a complex composition and include fibrinogen and a variable amount of cross-linking. Plasmic degradation of cross-linked fibrin forms a heterogeneous group of degradation products reactive in assays for D-dimer, and their levels provide a measure of the amount of fibrin formation and lysis. Caution should be exercised in comparing quantitative results using different assays because of problems with standardization and variable reactivity with different molecular forms. Marked elevations of fibrin(ogen) degradation products are a constant finding in experimental animal models of DIC. In human models of DIC resulting from endotoxin infusion, D-dimer is elevated early and high levels persist, reflecting lysis of microvascular fibrin deposits. Elevated levels of D-dimer and soluble fibrin are very sensitive for the diagnosis of DIC, and a normal level has a high negative predictive value. Serial monitoring of soluble fibrin or D-dimer assays may be of value in evaluating the response to therapy and possibly in identifying at-risk patients.

KEYWORD

Fibrin(ogen) degradation products - D-dimer - soluble fibrin - disseminated intravascular coagulation - DIC - endotoxin

REFERENCES

  • 1 Sasaki T, Page I H, Shainoff J R. Soluble complex of fibrinogen and fibrin.  Science . 1966;  152 1069-1071
    PubMedGoogle Scholar
  • 2 Jakobsen E, Ly B, Kierulf P. Incorporation of fibrinogen into soluble fibrin complexes.  Thromb Res . 1974;  4 499-507
    CrossrefPubMedGoogle Scholar
  • 3 Greenberg C S, Miraglia C C, Rickles F R, Shuman M A. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.  J Clin Invest . 1985;  75 1463-1470
    PubMedGoogle Scholar
  • 4 Ly B, Jakobsen E. Some aspects of the bonds interlinking soluble fibrin complexes in human plasma.  Thromb Res . 1975;  6 65-73
    CrossrefPubMedGoogle Scholar
  • 5 Seneri G GN, Gensini G F, Abbate R, Favilla S. Occurrence of soluble very-high-molecular-weight fibrinogen complexes in hypercoagulable states. An in vitro and in vivo study on their features.  Thromb Haemost . 1979;  42 1561-1573
    PubMedGoogle Scholar
  • 6 Francis C W, Connaghan D G, Scott W L, Marder V J. Increased plasma concentration of crosslinked fibrin polymers in acute myocardial infarction.  Circulation . 1987;  75 1170-1177
    PubMedGoogle Scholar
  • 7 Grøn Bennick A, Nieuwenhuizen W, Brosstad F. Normal and fibrinaemic patient plasma contain high-molecular-weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A.  Thromb Res . 1990;  57 259-270
    CrossrefPubMedGoogle Scholar
  • 8 Marder V J, Budzynski A Z. Data for defining fibrinogen and its plasmic degradation products.  Thrombosis et Diathesis Haemorrhagica . 1975;  33 199-207
    PubMedGoogle Scholar
  • 9 Francis C W, Marder V J, Barlow G H. Plasmic degradation of crosslinked fibrin: Characterization of new macromolecular soluble complexes and a model of their structure.  J Clin Invest . 1980;  66 1033-1043
    PubMedGoogle Scholar
  • 10 Francis C W, Marder V J. A molecular model of plasmic degradation of crosslinked fibrin.  Semin Thromb Haemost . 1982;  8 25-35
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Pizzo S V, Taylor Jr M L, Schwartz M L. Subunit structure of fragment D from fibrinogen and cross-linked fibrin.  J Biol Chem . 1973;  248 4584-4590
    PubMedGoogle Scholar
  • 12 Gaffney P J, Brasher M. Subunit structure of the plasmin- induced degradation products of crosslinked fibrin.  Biochim Biophys Acta . 1973;  295 308-313
    PubMedGoogle Scholar
  • 13 Gaffney P J, Lane D A, Kakkar V V. Characterization of a soluble D-dimer-E complex in crosslinked fibrin digests.  Thromb Res . 1975;  7 89-99
    CrossrefPubMedGoogle Scholar
  • 14 Alkjaersig N, Davies A, Fletcher A. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.  Thromb Haemost . 1977;  38 524-525
    PubMedGoogle Scholar
  • 15 Francis C W, Marder V J, Martin S E. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular soluble complexes.  Blood . 1980;  56 456-464
    PubMedGoogle Scholar
  • 16 Lane D A, Preston F E, VanRoss M E, Kakkar V V. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.  Br J Haematol . 1978;  40 609-615
    PubMedGoogle Scholar
  • 17 Graeff H, Hafter R, Bachmann L. Subunit and macromolecular structure of circulating fibrin from obstetric patients with intravascular coagulation.  Thromb Res . 1979;  16 313-328
    CrossrefPubMedGoogle Scholar
  • 18 Connaghan D G, Francis C W, Lane D A, Marder V J. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.  Blood . 1985;  65 589-597
    PubMedGoogle Scholar
  • 19 Proietti A B, McGuire M, Bell W. Specific identification of fibrin(ogen) degradation products in plasma and serum using blotting and peroxidase labeled antiserum.  Am J Hematol . 1990;  34 270-274
    PubMedGoogle Scholar
  • 20 Shainoff J R, Valenzuela R, Urbanic D A. Fibrinogen Aα and γ-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease.  Blood Coagul Fibrinolysis . 1990;  1 499-503
    PubMedGoogle Scholar
  • 21 Pfitzner S A, Dempfle C E, Matsuda M. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.  Thromb Haemost . 1997;  78 1069-1078
    PubMedGoogle Scholar
  • 22 Grøn Bennick A, Nieuwenhuizen W, Brosstad F. Normal and fibrinaemic patient plasma contain high-molecular weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A.  Thromb Res . 1990;  57 259-270
    CrossrefPubMedGoogle Scholar
  • 23 Kierulf P. Studies on soluble fibrin in plasma. II. N-terminal analysis of a modified fraction 1 (Cohn) from patient plasmas.  Scand J Clin Lab Invest . 1973;  31 37-42
    PubMedGoogle Scholar
  • 24 Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation: The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products.  J Lab Clin Med . 1971;  77 665-676
    PubMedGoogle Scholar
  • 25 Godal H C, Abildgaard U. Gelation of soluble fibrin in plasma by ethanol.  Scand J Haematol . 1966;  3 342-350
    PubMedGoogle Scholar
  • 26 Matthias F R, Reinicke R, Heene D L. Affinity chromatography and quantitation of soluble fibrin from plasma.  Thromb Res . 1977;  10 365-384
    CrossrefPubMedGoogle Scholar
  • 27 Hurlet-Jensen A, Cummins H Z, Nossel H L. Fibrin polymerization and release of fibrinopeptide B by thrombin.  Thromb Res . 1982;  27 419-427
    CrossrefPubMedGoogle Scholar
  • 28 Higgins D L, Lewis S D, Shafer J A. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin.  J Biol Chem . 1983;  258 9276-9282
    PubMedGoogle Scholar
  • 29 Schielen W JG, Adams H H M P, van Leuven K. The sequence γ-(312-324) is a fibrin-specific epitope.  Blood . 1991;  77 2169-2173
    PubMedGoogle Scholar
  • 30 Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexes with fibrinogen or its derivatives: Its application to the measurement of soluble fibrin in plasma.  Blood . 1996;  88 2109-2117
    PubMedGoogle Scholar
  • 31 Carville D G, Dimitrijevic N, Walsh M. Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction.  Clin Chem . 1996;  42 1537-1541
    PubMedGoogle Scholar
  • 32 Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay.  Thromb Haemost . 1986;  55 189-193
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Halvorsen S, Skjonsberg R R, Godal H C. Comparison of methods for detecting soluble fibrin in plasma, an in vitro study.  Thromb Res . 1990;  57 489-497
    CrossrefPubMedGoogle Scholar
  • 34 McCarron B I, Marder V J, Francis C W. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.  Thromb Haemost . 1999;  82 1722-1729
    PubMedGoogle Scholar
  • 35 Brenner B, Francis C W, Marder V J. The role of soluble crosslinked fibrin in D-dimer immunoreactivity of plasmic digests.  J Lab Clin Med . 1989;  113 682-688
    PubMedGoogle Scholar
  • 36 McCarron B I, Marder V J, Kanouse J J, Francis C W. A soluble fibrin standard: Comparable dose-response with immunologic and functional assays.  Thromb Haemost . 1999;  82 145-148
    PubMedGoogle Scholar
  • 37 Connaghan D G, Francis C W, Ryan D H, Marder V J. Prevalence and clinical implications of heparin-associated false-positive tests for serum fibrin(ogen) degradation products.  Am J Clin Pathol . 1986;  86 304-310
    PubMedGoogle Scholar
  • 38 Ginsberg J S, Wells P S, Brill-Edwards P. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism.  Thromb Haemost . 1995;  73 35-38
    PubMedGoogle Scholar
  • 39 Uchiba M, Okajima K, Murakami K. Effect of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats.  Thromb Res . 1998;  89 233-241
    CrossrefPubMedGoogle Scholar
  • 40 Drake T A, Cheng J, Chang A. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis [published erratum appears in Am J Pathol 1993;92:143-149].  Am J Pathol . 1993;  91 2850-2856
    PubMedGoogle Scholar
  • 41 Kruithof E K, Mestries J C, Gascon M P. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation-effect of interleukin-6.  Thromb Haemost . 1997;  77 905-910
    PubMedGoogle Scholar
  • 42 Creasey A A, Chang A C, Feigen L. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest . 1993;  91 2850-2856
    CrossrefPubMedGoogle Scholar
  • 43 Pajkrt D, van der Poll T, Levi M. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.  Blood . 1997;  89 2701-2705
    PubMedGoogle Scholar
  • 44 Pernerstorfer T, Hollenstein U, Hansen J B. Lepirudin blunts endotoxin-induced coagulation activation.  Blood . 2000;  95 1729-1734
    PubMedGoogle Scholar
  • 45 Yu M, Nardella A, Lechet L. Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis.  Crit Care Med . 2000;  28 1777-1780
    PubMedGoogle Scholar
  • 46 Okajima K, Uchiba M, Murakami K. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.  Am J Hematol . 1996;  51 186-191
    CrossrefPubMedGoogle Scholar
  • 47 Carr J M, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer.  Am J Clin Pathol . 1989;  91 280-287
    PubMedGoogle Scholar
  • 48 Bick R L, Baker W F. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC).  Thromb Res . 1992;  65 785-790
    CrossrefPubMedGoogle Scholar
  • 49 Wada H, Wakita Y, Nakase T. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation.  Am J Hematol . 1996;  51 255-260
    CrossrefPubMedGoogle Scholar
  • 50 Lane D A, Ireland H, Knight I. The significance of fibrinogen derivatives in plasma in human renal failure.  Br J Haematol . 1984;  56 251-260
    PubMedGoogle Scholar
  • 51 van de Water L, Carr J M, Aronson D. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.  Blood . 1986;  67 1468-1473
    PubMedGoogle Scholar
  • 52 Bounameaux H, de Moerloose P, Perrier A. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview [see comments].  Thromb Haemost . 1994;  71 1-6
    PubMedGoogle Scholar
  • 53 Elias A, Aptel I, Huc B. D-dimer test and diagnosis of deep vein thrombosis: A comparative study of 7 assays.  Thromb Haemost . 1996;  76 518-522
    PubMedGoogle Scholar
  • 54 van Beek J E, van den Ende B, Berckmans R J. A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism.  Thromb Haemost . 1993;  70 408-413
    PubMedGoogle Scholar
  • 55 Gaffney P J, Edgell T, Creighton-Kempsford L J. Fibrin degradation product (FnDP) assays: Analysis of standardization issues and target antigens in plasma.  Br J Haematol . 1995;  90 187-194
    PubMedGoogle Scholar
  • 56 Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies [see comments].  Chest . 1992;  101 816-823
    CrossrefPubMedGoogle Scholar
  • 57 Gando S, Kameue T, Nanzaki S. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.  Thromb Haemost . 1996;  75 224-228
    PubMedGoogle Scholar
  • 58 Wada H, Sakuragawa N, Mori Y. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.  Am J Hematol . 1999;  60 273-278
    CrossrefPubMedGoogle Scholar